Aurora Technologies will begin routinely upgrading its installed base of about 20 dedicated breast MR scanners with an acquisition capability that boosts signal-to-noise by 300%, according to the company. The upgrade, called spiral RODEO (Rotating Delivery of Excitation Off-resonance), was commercially launched at the RSNA meeting.
Aurora Technologies will begin routinely upgrading its installed base of about 20 dedicated breast MR scanners with an acquisition capability that boosts signal-to-noise by 300%, according to the company. The upgrade, called spiral RODEO (Rotating Delivery of Excitation Off-resonance), was commercially launched at the RSNA meeting.
Rather than acquiring data line-by-line, as happens in a conventional fat saturation 3D Fourier transformation, the new approach acquires data from the center of the field-of-view outward in a spiral pattern.
"With spiral RODEO, we are acquiring data 46% of the time, compared to a typical fat-sat acquisition, which does so about 9% of the time," said Dr. Steven Harms, medical director at Aurora.
Current users of the 1.5T Aurora system will get the upgrade first. Facilities that order the breast MR system will receive spiral RODEO automatically, according to Debbie Thomas, vice president of marketing for Aurora.
"Our goal is to have all existing Aurora users upgraded starting right after the RSNA meeting and going into December and next year," she said. "Then we'll continue rolling it out for new orders. The earliest of these, if someone orders today, would be February."
Spiral RODEO was cleared by the FDA almost a year ago and shown as a work-in-progress at the 2005 RSNA meeting. It entered clinical testing in June 2006 at the Breast Center of Northwest Arkansas in Fayetteville, a women's health center operated by Harms, who keeps one foot on the clinical side and the other on the corporate. Harms developed RODEO several years ago, while serving as the director of imaging research at the University of Arkansas in Little Rock.
When applied after contrast injection, this proprietary pulse sequence reduces signal from normal ductal tissue and, thereby avoids false-positive enhancement from benign lesions and dense fibroglandular tissue, according to Harms. The spiral version improves signal-to-noise by a factor of three, he said. This translates into dramatically improved acquisitions: 160 slices with images at 512 x 512 pixels.
Spiral RODEO is a proprietary capability of Aurora. The company's 1.5T scanner was specially designed with oscillating gradients to support this pulse sequence.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.